 Hey guys, how you doing? This is your boy Rich from Rich TV Live and you too can join the club at richpakesdaily.com where you can learn how to win and trade. Hi, how's everybody doing today? I'm your host, Rich from Rich TV Live with our very special guest, Chris Shaber, the CEO of Solid Genics. How you doing today, Chris? Great, Rich, thanks for having me. My pleasure, excited to learn more about you and your company. Can you tell us a little bit about yourself and how you got involved with Solid Genics? Sure, sure, I'm gonna show my age a little bit now but I've been in this business quite some time, 32 years in both big pharma as well as startup biotech and with most of my time in the startup biotech arena, really dealing with very novel drugs in mainly in rare disease settings and really have prodded myself over those 32 years to really learning the business and especially the drug development business from pre-clinical research through to commercialization. So it's really allowed me as a CEO of a startup company to really understand the different aspects of what we're doing here and really be able to move those forward effectively. With regard to Solid Genics, believe it or not, almost half my career has been at Solid Genics. I've been here quite some time. I knew some of the board members and they asked me to really build out a pipeline and from my background, that's what I had done. I came and joined as CEO and really with a pretty much a clean slate build out a very robust pipeline that I think is now pretty exciting and late stage. Congratulations on all your success thus far. My next question is, can you tell us what are some of the milestones for Solid Genics has set for 2022 which shareholders can really look forward to? You know, as I noted, the robust pipeline really allows for a number of milestones. Our lead program is a drug brand name hybrid for a cancer or chronic cancer called cutaneous T cell lymphoma or CTCL for short. And there we've already completed a phase three clinical trial successfully. So those not familiar, phase three is that registration study that you then submit to the FDA or any worldwide health authority for potential approval. With that successful study, now this year we're preparing that new drug application to file to the FDA and we'll be filing that in the second half of this year. So a very exciting time for us after a number of years of drug development to really be able to position the program to file to the FDA and CTCL is a rare cancer where lesions or plaques, tumors on the skin develop and you need to treat them. And we treat them with a very novel topical agent you apply to the lesion or plaque and you activate it with a proprietary light device which is essentially fluorescent light, safe visible fluorescent light to reduce or shrink the lesion on the skin. So a very safe efficacious approach from the data we've seen so that's our lead program. We then behind that with that same active ingredient in hybrid we're also looking to do the same thing in mild tomato psoriasis a much larger indication in CTCL but an area of medical need. A phase two study will start in the second half of this year for that. And so that's where a lot of our focus has been. I think what's unique with Solagenix we also have a separate segment of our business that we call our public health solution segment. This focuses on a number of heat stable vaccines for infectious disease, for bio defense applications that are funded entirely by the government. While I've been with the company over my 16 years we've received an excess of $75 million of non-volutive government funding to manage our programs, offset our burn. So as you imagine with that additional funding in addition to raising capital in the open markets it's really nice to build out a more robust pipeline multiple shots on goal and mitigate risk like a financial portfolio actually. Chris, can you tell us about the management here at Rich TV Live? I really love to understand the fundamentals and the team behind the projects. So can you explain a little bit about the management at Solagenix especially their past success in the public markets? No, it's great question. And as you would imagine in a SART company whether it's biotech or any other area there's multitasking, right? You really need individuals that have expertise not only a core competency in one particular area but can wear multiple hats and advancing the company forward. And what I've done over the years is worked with a number of individuals that we've successfully developed a number of drugs together and I brought many of them along with me. So they're here at Solagenix from previous companies. Some even have followed me to companies. So my chief medical officer has been with me for a number of years. We worked together and brought a very novel therapy to market and in a previous company we're looking to do it again here with hybrid and CTCL in addition to my chief scientific officer or my vice president of regulatory affairs. So I think to your point and to the question is really to find people that have that competency that can do that but have that expertise and it really allows for an acceleration when you actually know the folks because you've worked with them before it's seamless, right? You move quickly or it's not that usual when you hire someone new you're evaluating them. We have a team, we know what we need to do and we drive forward with it. And we've been able to demonstrate in previous successes of advancing technology in some company myself I've done it with a number of companies including one I co-founded which was known as discovery laboratories that developed the technology for newborn babies where I led the charge of that development. My chief medical officer and I developed the therapy which he then went and was involved with starting a company around that around again, another neonatal indication. So we've done that, we've had our successes and that's what you wanna see, right? Is not only the successes in the drug development but have these successes translated to commercial value for shareholders and we've been able to do that and are hoping to do it again here at Souljacks even though right now there's some difficult markets out there. Yeah, they've definitely been difficult markets. Now in this difficult market you guys have still been able to announce approximately 1.4 million in non-dilutive funding via government tax programs, multiple government tax programs. Can you tell us about this and what it means for the company? You know, as I noted earlier we've had a level of success in securing non-dilutive government funding and just as we're aggressive in drug development we're also aggressive in trying to pursue that non-dilutive funding because as we noted these markets, you know, they're volatile and at any time during the drug development process drug development takes a lot of time, right? So you really need to be able to fuel an engine to really advance therapies and enroll patients and get the studies done. And so we've looked at a number of ways where we could secure non-dilutive funding not over dilute the shareholder and really extend cash runway. And the recent announcement I had was through the New Jersey state tax credit program you get monies for your R&D selling your R&D tax credits. So we've been in that program for a number of years we brought in roughly, you know seven and a half, $8 million through that program. So it all adds up, right? And it's very helpful and has really gotten us in part to where we are today. Chris, if Solagenics were to compare itself to its competitors in the biopharmaceutical sector what would you say sets you guys apart? You know, the one thing that points out is something that I've mentioned a couple of times now it's that non-dilutive government funding, right? A lot of times you'll see startup companies and they cannot extend cash runway the markets become difficult and they can't raise capital to continue. We've tried to structure a pipeline that allows for multiple opportunities to fund in addition to advanced good technology. And we've been able with that 75 and excess of $75 million have been able to really extend that cash runway. And more importantly to whether these little storms of market volatility to continue to move the company forward and advance programs. So I think that's one unique measure of not only of having this two segment business where we have this government funding instrument that continues to allow us to defray expense and build out a robust pipeline. Now here at Rich TV Live we love to understand your share structure. So can you go through the capital structure of Solid Genics for our viewers and how you plan on attracting more institutional investment alongside more retail investors? Great question, Rich. Roughly we're at about a $23 million market cap extremely low for where we are with a essentially filing a new drug application for potential approval later this year. Our shares outstanding roughly about 43 million. We have some stock options in addition around 2.2 million, very little warrants. A lot of times with Sarp Company especially in Biotech you'll hear a lot of warrant coverage. We have roughly 60,000 warrants extremely, extremely low. We do have a portion of debt through a very well-known fund called Pontifax about 10 million which is convertible at $4.10 fully diluted or roughly about 48 million. No preferred shares out there and nothing outstanding. We have the grant revenue as I noted, cash as of March 22nd, 2022 of roughly $23 million and a quarterly average burn of about 3.2 million. So relatively low quarterly burn for the pipeline we have that extends our cash runway into mid 2023. The only other thing I'll add is that you're always wanting to maintain potential instruments that allow for additional funding to come in. Not only that non-diluted of government grant and contract funding, but we do have an at the market vehicle that we can sell shares on the market through B Riley roughly about 26 million at our disposal. We don't use it as a primary funding source just to supplement cash but that adds another 26 million potentially to our cash runway if needed. And one thing that we are doing to your point about attracting institutional investors is you know, many times these institutional investors are looking for deals, right? They want the discounts, they want the warrants. We don't need cash today, right? We're not selling a deal, we're advancing the pipeline with a deal to come potentially in 2023. But I'm very active on the investor relations, public relations, when I'm speaking to a number of investors, both institutional and retail family office just getting the story out there, the message out there. And I think that's something that's very important now especially with the markets currently. And we've seen a little bit of momentum in our stock recently over the last few days with some of those discussions, hopefully more to follow. And one thing is I will be in front of those institutional investors. And if a good fundamental institutional investor says to me, hey Chris, I wanna take a position in your company. I'm sure my board and I will entertain that depending on the quality of the name and if they're long in the stock. But it's really to get the message out to as many folks as possible, institutional and retail and family office and just continue to increase awareness on what we're doing here. Chris, if there was one thing you would want shareholders to know about Solagenics today, what would that be? You know, I have to say, I mean, if those individuals that are familiar with the drug development process, how long it takes in the risk profile associated with it, where we sit today with our hybrid and cutaneous T cell opoma or CTCL, this is about as de-risk as you get after being through all the clinical trials showing success, now having to file that data with the FDA, we're at a very nice inflection point. Unfortunately, the frustrating thing for me is a potential positive for an investor, right? Is the stock price is severely depressed, we're trading below cash with an asset that's already demonstrated positive data and face to it, we're filing an NDA. It's a nice entry point at roughly about 55 cents to get into this stock. What is the best way for investors to get in touch with the company if they have any questions about Solagenics? Obviously you could always call directly at the company number and we make it a point to make sure we're very active with our investors keeping them updated. On our website at solagenics.com, we also, in the upper right hand corner, there's a contacts and if you click that, you can write an email and if you put investor relations or business development, depending on what it is, those come directly to me and I respond or one of my associates responds, but we're very prompt and responding to any inquiries. We're also very good, I think, as a public company, putting a lot of information out there. We have on our website, we have a lot of information, presentations, fact sheets. We have a YouTube channel with short videos that summarizes what we're doing here and where we are and to some of the questions you asked, Rich, what are the key milestones? And I hit those in a short video very carefully. So we try to put as much information out as possible so that people are informed and kind of know where we are. We're an exciting inflection point right now and there's a lot of momentum behind us internally to drive, to file and we're expecting important things, good things in the next six to 12 months. Well, thank you so much for your time today. The CEO of Solagenix, Chris Shaber. Thank you for joining us today, Chris. Oh, Rich, thanks for having me. I'd love to join again and keep you updated on our accomplishments. Always a pleasure and we wish you all the best of luck on your future endeavors. I wanna make sure everybody puts Solagenix on their radar and on their watch list. Symbol is SNGX on the NASDAQ. You can also go and learn more at richtv.io, a community ecosystem built by investors for investors. Now, I must remind you guys that Rich TV Live is strictly for information, education and entertainment purposes. Please do your due diligence, do your research before you invest in anything we talk about or discuss here on Rich TV Live. In saying that, this is a company that we believe is undervalued, under-appreciated and under-exposed. If you like the video, please smash the like button, comment down below, share the video everywhere and subscribe. This is your host, Rich from Rich TV Live. If you're not winning, you're probably not watching. We bring you the winners and we bring them to you first. What do you guys think about Solagenix? Love to know what you guys think. Comment on the video. This is Rich from Rich TV Live with Chris Shaber, the CEO of Solagenix saying, have a nice day everybody. We'll see you soon.